Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer. Treatment or prevention of thrombosis poses an additional challenge in everyday clinical practice. A therapy using the active ingredient rivaroxaban specifically tailored to children was successfully tested for the first time in 2020. Now, long-term data … Read more
Patients with pulmonary embolism (PE) who were treated with mechanical thrombectomy (MT) within 12 hours of hospital admission had significantly better pulmonary outcomes than patients treated with mechanical thrombectomy more than 12 hours after admission, based on new data from the FLASH registry. The benefits of prompt treatment with MT for patients with high-risk PE … Read more
TOPLINE: In a modeling analysis, initiating direct acting or nonvitamin K oral anticoagulants (DOAC/NOAC) in patients with device-detected subclinical atrial fibrillation (AF) provided a net gain of approximately 1 additional quality-adjusted week of life per patient over 10 years, equating to a 65.8% chance of treatment offering more benefits than withholding it. METHODOLOGY: Previous randomized … Read more
CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at least 6 months of anticoagulant treatment after a clot, and results in a lower rate of clinically relevant bleeding, the API-CAT trial shows. “Our results indicate … Read more
A blood test conducted in a prehospital setting may rapidly distinguish between ischemic and hemorrhagic stroke, potentially facilitating more rapid, targeted treatment. The test measures the levels of glial fibrillary acidic protein (GFAP), a protein specific to the brain which is released into the bloodstream when brain cells are damaged or destroyed. It is already … Read more